The current financial score of Sellas Life Sciences Group Inc is 6.98. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Sellas Life Sciences Group Inc is 9.55. Its current P/E ratio is -50.34, which is -99.25% below the recent high of -0.38 and -34.20% above the recent low of -67.56.
The current earnings forecast score of Sellas Life Sciences Group Inc is 8.00. The average price target is 32.50, with a high of 35.00 and a low of 30.00.
The current price momentum score of Sellas Life Sciences Group Inc is 4.98. Currently, the stock price is trading between the resistance level at 14.46 and the support level at 9.68, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sellas Life Sciences Group Inc is 3.00. The latest institutional shareholding proportion is 26.02%, representing a quarter-over-quarter increase of 25.11%. The largest institutional shareholder is James Simons, holding a total of 310.36K shares, representing 0.01% of shares outstanding, with 10966.67% increase in holdings.
The current risk assessment score of Sellas Life Sciences Group Inc is 3.63. The company's beta value is 2.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.